Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

569 result(s) found, displaying 51 to 75

  • AusPAR: Pegcetacoplan

    Australian public assessment report (AusPar)
    New AusPAR for Empaveli (pegcetacoplan) for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria.

  • AusPAR: Tecentriq

    Australian public assessment report (AusPar)
    New AusPAR for Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.

  • AusPAR: VeraSeal

    Australian public assessment report (AusPar)
    VeraSeal (human fibrinogen and human thrombin) for the supportive treatment of hemostasis.

  • AusPAR: Nuvaxovid homologous booster

    Australian public assessment report (AusPar)
    Nuvaxovid homologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.

  • AusPAR: Nuvaxovid heterologous booster

    Australian public assessment report (AusPar)
    Nuvaxovid heterologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.

  • AusPAR: Remdesivir

    Australian public assessment report (AusPar)
    New AusPAR for VEKLURY (remdesivir ) for the treatment of coronavirus disease 2019 in paediatric and adult patients.

  • AusPAR: Belumosudil

    Australian public assessment report (AusPar)
    New AusPAR for Rholistiq (belumosudil) for the treatment of patients with chronic graft-versus-host disease aged 12 years and older.

  • AusPAR: Dupilumab

    Australian public assessment report (AusPar)
    New AusPAR for Dupixent (dupilumab) for the treatment of atopic dermatitis and chronic rhinosinusitis with nasal polyposis.

  • AusPAR: Lurbinectedin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Lurbinectedin

  • AusPAR: Luspatercept

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Luspatercept

  • AusPAR: Venetoclax

    Australian public assessment report (AusPar)
    New AusPAR for Venclexta (venetoclax) for acute myeloid leukaemia indication, provisional to full registration.

  • AusPAR: Inclisiran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Inclisiran

  • AusPAR: Amifampridine

    Australian public assessment report (AusPar)
    New AusPAR for Ruzurgi (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome.

  • AusPAR: Tozinameran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Tozinameran

  • AusPAR: Forxiga

    Australian public assessment report (AusPar)
    Forxiga (dapagliflozin) has been approved for reducing the risk of progressive decline in kidney function in adults with
    proteinuric chronic kidney disease.

  • AusPAR: Sacituzumab govitecan

    Australian public assessment report (AusPar)
    New AusPAR for Trodelvy (sacituzumab govitecan) for the treatment of breast cancer.

  • AusPAR: lemborexant

    Australian public assessment report (AusPar)
    New AusPAR for Dayvigo (lemborexant) for the treatment of insomnia.

  • AusPAR: Tixagevimab and cilgavimab

    Australian public assessment report (AusPar)
    New AusPAR for EVUSHELD (tixagevimab and cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years older

  • AusPAR: Eptinezumab

    Australian public assessment report (AusPar)
    New AusPAR for Vyepti (eptinezumab) for the preventive treatment of migraine in adults.

  • AusPAR: Elasomeran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Elasomeran

  • AusPAR: ChAdOx-1-S

    Australian public assessment report (AusPar)
    New AusPAR for Vaxzevria (ChAdOx-1-S) for the prevention of COVID-19 caused by SARS-CoV-2

  • AusPAR: Molnupiravir

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Molnupiravir

  • AusPAR: Tozinameran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Tozinameran